Last viewed: ADXS

Prices are updated after-hours

ADXS

Advaxis, Inc.

ADXS | $0.572 12.48% 2.5K

|

Health Technology

(0.0% 1d) (-9.5% 1m) (-55.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-88.99% volume)
Earnings Calendar: 2022-09-08
Market Cap: $ 24,386,305
http://www.advaxis.com
Sec Filling | Patents | 35 employees

(US) Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

cancer prostate cancer immunotherapy

add to watch list Paper trade email alert is off

Press-releases

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
IMNM | $15.31 -1.1% -1.11% 1.3M

|

Health Technology

| -40.87% | O: -1.32% H: 1.76% C: -9.8%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -21.8% | O: 2.74% H: 17.51% C: 5.22%
al102 tumors pharmaceuticals study

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M

|

Health Technology

| -6.97% | O: 0.61% H: 0.77% C: -0.66%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -35.96% | O: 6.74% H: 0.0% C: -10.53%
al102 drug tumors pharmaceuticals designation

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M

|

Health Technology

| -12.96% | O: -0.19% H: 0.66% C: -0.62%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -36.67% | O: 0.0% H: 5.56% C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2

Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -38.87% | O: -3.49% H: 0.0% C: 0.0%
pharmaceuticals

Lisa Carey
Published: 2023-08-24 (Crawled : 19:00) - atyrpharma.com
PSTX | $2.16 6.93% 6.48% 550K

|

Health Technology

| -8.51% | O: 0.85% H: 0.42% C: -11.39%
LIFE | $1.63 1.88% 1.84% 290K

|

Health Technology

| -10.87% | O: 0.0% H: 3.26% C: 0.54%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -45.06% | O: 1.2% H: 0.0% C: -4.76%

Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte
Published: 2023-07-31 (Crawled : 09:00) - prnewswire.com
TYRA | $15.52 3.61% 3.48% 68K

|

Health Technology

| 8.01% | O: -0.42% H: 8.05% C: 3.71%
ALPMY | News | $9.5 -1.11% 1M

|

| -35.82% | O: 0.34% H: 1.07% C: -1.81%
LLY | News | $731.33 0.69% 0.0% 2.3M

|

Health Technology

| 59.51% | O: -0.44% H: 0.0% C: 0.0%
URGN | $14.37 4.66% 4.45% 280K

|

Health Technology

| -36.44% | O: -1.59% H: 0.94% C: -2.65%
SNY | News | $47.125 1.78% 1.75% 2.1M

|

Health Technology

| -10.83% | O: 3.56% H: 0.0% C: 0.0%
NKTR | News | $1.37 10.48% 9.49% 2M

|

Health Technology

| 149.54% | O: -0.73% H: 4.99% C: -0.96%
INCY | $51.92 -0.82% -0.83% 1.8M

|

Health Technology

| -17.7% | O: -0.03% H: 1.4% C: 1.03%
ARAV | $0.0401 4.74% 4M

|

Health Technology

| -96.72% | O: 6.38% H: 0.33% C: -6.67%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -51.28% | O: -1.71% H: 3.48% C: -5.43%
companies expected growth market

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Published: 2023-07-27 (Crawled : 12:20) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M

|

Health Technology

| -22.02% | O: -3.21% H: 2.51% C: -0.44%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -43.56% | O: 6.93% H: 3.7% C: 1.85%
pharmaceuticals agreement

Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight
Published: 2023-07-05 (Crawled : 21:00) - prnewswire.com
ALPMY | News | $9.5 -1.11% 1M

|

| -33.32% | O: 0.86% H: 0.0% C: -1.01%
NVS | News | $95.12 0.81% -1.18% 2.4M

|

Health Technology

| -4.22% | O: -1.17% H: 0.63% C: 0.22%
LLY | News | $731.33 0.69% 0.0% 2.3M

|

Health Technology

| 57.04% | O: -0.55% H: 0.97% C: 0.02%
VERU | $1.27 -3.05% -3.15% 1.4M

|

Health Technology

| 5.83% | O: -0.83% H: 0.0% C: -6.72%
OPK | $1.23 0.0% 3.6M

|

Health Technology

| -41.43% | O: -1.19% H: 1.2% C: -0.72%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -40.0% | O: 0.0% H: 0.0% C: -6.83%
cancer global growth market

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M

|

Health Technology

| -23.73% | O: -0.19% H: 1.07% C: 0.65%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -43.56% | O: 1.24% H: 0.0% C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M

|

Health Technology

| -25.16% | O: 0.37% H: 0.85% C: 0.12%
ADXS | $0.572 12.48% 2.5K

|

Health Technology

| -55.47% | O: -2.73% H: 4.42% C: -0.4%
meeting results phase 2

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001178913-24-000828	4	2024-03-06	2024-03-01	Buy	M	2250000	13462500
0001178913-24-000828	4	2024-03-06	2024-03-01	Buy	M	2250000	7837500
0001178913-24-000828	4	2024-03-06	2024-03-01	Buy	M	1500000	11212500
0001178913-24-000828	4	2024-03-06	2024-03-01	Buy	M	1500000	5587500
0001178913-24-000828	4	2024-03-06	2024-03-01	Sell	M	3750000	9712500
0001178913-24-000828	4	2024-03-06	2024-03-01	Sell	M	3750000	4087500
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	8062500	13462500
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	8437500	7837500
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	1295813	14758313
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	3887438	11724938
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	4237687	18996000
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	M	1926221	13661159
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	F	2586905	25130903
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	8062500	27717808
0001178913-24-000480	4	2024-02-12	2024-02-07	Sell	F	2707581	20661639
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	8437500	23369220
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	1295813	19655308
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	3887438	14931720
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	4237687	18359495
0001178913-24-000480	4	2024-02-12	2024-02-07	Buy	M	1926221	11044282

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M

|

AGBA | $2.565 105.2% 51.27% 200M

|

MLEC | $2.44 74.29% 42.62% 78M

|

EDBL | News | $6.28 67.02% 40.13% 16M

|

ATGL | $2.91 48.81% 32.8% 180K

|

ZAPP | $0.2175 47.16% 32.05% 16M

|

ONFO | $0.6075 38.38% 27.74% 7.3M

|

VIVK | $1.48 38.32% 27.7% 530K

|

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M

|

SDIG A | $3.635 35.13% 26.0% 1M

|

Last 48 Hours Insiders Buying

MCFT P 26039 | $21.5 1.9% 1.86% 110K

|

Consumer Durables

| 00:00
YORW P 29 | $35.43 1.03% 1.02% 66K

|

| 19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K

|

Electronic Technology

| 17:00
BANF P 256 | $91.28 2.24% 2.18% 150K

|

| 15:30
RMCF | $3.56 0.28% 0.28% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar